Antiviral treatment of rhinotracheitis virus-, immunodeficiency virus- and leukemia virus infections in the cat;Antivirale behandeling van rhinotracheïtisvirus-, immunodeficië ntievirus- en leukemievirusinfecties bij de kat

Vlaams Diergeneeskundig Tijdschrift

Volumn 74, Issue 6, 2005, Pages 420-431

  Neirinckx, E ^a   Garre B ^a   Nauwynck, H ^a   Croubels, S ^a   De Backer, P ^a   Van Der Meulen, K ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 30644468040     PISSN: 03039021     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Arai M., Earl D.D., Yamamoto J.K. (2002). Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Veterinary Immunology and Immunopathology 85, 189-204.
2. Beaumont S.L., Maggs D.J., Clarke H.E. (2003). Effects of bovine lactoferrin on in vitro replication of feline herpesvirus. Veterinary Ophtalmology 6, 245-250.
3. Bisset L.R., Lutz H., Böni J., Hofmann-Lehmann R., Lüthy R., Schüpbach J. (2002). Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Research 53, 35-45.
4. Bittle J.L., Peckham J.C. (1971). Genital infection induced by feline rhinotracheitis virus and effects on newborn kittens. Journal of the American Veterinary Medical Association 158, 927-928.
5. Block A., Hartmann K., Lutz H., Kraft W. (1997). Plazebokontrollierte Doppelblindstudie über die Wirksamkeit eines Paramunitätsinducers bei natürlich FeLV-infizierten Katzen. Tierärztliche Praxis 25, 261-266.
6. Boucher C.A., Cammack N., Schipper P., Schuurman R., Rouse P., Wainberg M.A., Cameron J.M. (1993). High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalyctic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy 37, 2231-2234.
7. Bouhanna L. (2004). Diagnostic et traitement de l'herpès oculaire chez le chat. Le Point Vétérinaire 251, 18-23.
8. Bradley W.G., Kraus L.A., Good R.A., Day N.K. (1995). Dehydroepiandrosterone inhibits replication of feline immunodeficiency virus in chronically infected cells. Veterinary Immunology and Immunopathology 46, 159-168.
9. Cox E. (1992). Feliene Leukemievirus Infectie: een Overzicht. Vlaams Diergeneeskundig Tijdschrift 61, 61-67.
10. Cummins J.M., Tompkins M.B., Olsen R.G., Tompkins W.A., Lewis M.G. (1988). Oral use of human alpha interferon in cats. Journal of Biological Response Modifiers 7, 513-523.
11. de Mari K., Maynard L., Sanquer A., Lebreux B., Eun H.-M. (2004). Therapeutic effects of recombinant feline interferon-ω on feline leukaemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. Journal of Veterinary Internal Medicine 18, 477-482.
12. Egberink H.F., Borst M., Niphuis H., Balzarini J., Neu H., Schellekens H., de Clercq E., Horzinek M., Koolen M. (1990). Suppression of Feline Immunodeficiency Virus Infection in vivo by 9-(2-Phosphonomethoxyethyl)Adenine. Proceedings of the National Academy of Sciences of the United States of America 87, 3087-3091.
13. Egberink H.F., Hartmann K., Horzinek M.C. (1991). Chemotherapy of feline immunodeficiency virus infection. Journal of the American Veterinary Medical Association 199, 1485-1487.
14. Galle L.E. (2004). Antiviral therapy for ocular viral disease. Veterinary Clinics of North America: Small Animal Practice 34, 639-653.
15. Glitz F. (2002). Wirkungen und Einsatzmöglichkeiten eines Immunmodulators (Baypamun®) bei Kleintieren und Kaninchen. Kleintierpraxis 47, 389-452.
16. Hart S., Nolte I. (1995). Long-term treatment of diseased, FIV-seropositive field cats with Azidothymidine (AZT). Journal of the American Veterinary Medical Association 42, 397-409.
17. Hartmann K., Donath A., Beer B., Egberink H.F., Horzinek M.C., Lutz H., Hoffmann-Fezer G., Thum I., Thefeld S. (1992). Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Veterinary Immunology and Immunopathology 35, 167-175.
18. Hartmann K., Kraft W. (1994). FeLV Infection. Revue de Médecine Vétérinaire 145, 191-197.
19. Hartmann K. (1998). Feline immunodeficiency virus infection: an overview. The Veterinary Journal 155, 123-137.
20. Hartmann K., Kuffer M., Balzarini J., Naesens L., Goldberg M., Erfle Goebel F.D., De Clercq E., Jindrich J., Holy A., Bischofberger N., Kraft W. (1998a). Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2- phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirals 17, 120-128.
21. Hartmann K., Block A., Ferk G., Vollmar A., Goldberg M., Lutz H. (1998b). Treatment of feline leukaemia virus-infected cats with paramunity inducer. Veterinary Immunology and Immunopathology 65, 267-275.
22. Hartmann K., Block A., Ferk G., Beer B., Vollmar A., Lutz H. (1999). Treatment of feline leukaemia virus (FeLV) infection. Veterinary Microbiology 69, 111-113.
23. Hoover E.A., Zeidner N.S., Mullins J.I. (1990). Therapy of presymptomatic FeLV-induced immunodeficiency syndrome with AZT in combination with alpha interferon. Annals of the New York Academy of Sciences 616, 258-269.
24. Hoover E.A., Mullins J.I. (1991). Feline leukemia virus infection and diseases. Journal of the American Veterinary Medical Association 199, 1287-1297.
25. Kashiwase H., Katsube T., Kimura T., Nishigaki T., Yamashita M. (2000). 8-Difluoromethoxy-4-quinolone derivates as anti-feline immunodeficiency virus (FIV) agents: important features for inhibitory activity of FIV replication. Journal of Veterinary Medical Science 62, 499-504.
26. Kölbl S., Skolek R., Hirt R., Seiser M., Thalhammer J. (2000). Klinische Studie an persistent virämischen Katzen mit FeLV-Infektion nach peroraler Langzeitapplikation von Interferon α. Kleintierpraxis 45, 493-568.
27. Kruth S.A. (1998). Biological Response Modifiers: Interferons, Interleukins, Recombinant Produkts, Liposomal Produkts. Veterinary Clinics of North America: Small Animal Practice 28, 269-295.
28. Larkins N. (2005). Potential implications of lactoferrin as a therapeutic agent. American Journal of Veterinary Research 66, 739-742.
29. Maggs D.J., Collins K.B, Thorne J.G., Nasisse M.P. (2000). Effects of L-lysine on in vitro replication of feline herpes-virus type-1. American Journal of Veterinary Research 61, 1474-1478.
30. Maggs D.J., Nasisse M.P., Kass P.H. (2003). Efficacy of oral supplementation with L-lysine in cats latently infected with feline herpesvirus. American Journal of Veterinary Research 64, 37-42.
31. Maggs D.J., Clarke H.E. (2004). In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. American Journal of Veterinary Research 65, 399-403.
32. Mayr B., Hörber D. (1992). Paramunisierung FeLV-positiver Katzen - ein Bericht aus der Praxis. Kleintierpraxis 37, 515-518.
33. McCaw D.L., Boon G.D., Jergens A.E., Kern M.R., Bowles M.A., Johnson J.C. (2001). Immunomodulation Therapy for Feline Leukemia Virus Infection. Journal of the American Animal Hospital Association 37, 356-363.
34. Nasisse M.P., Guy J.S., Davidson M.G., Sussman W., De Clercq E. (1989). In vitro susceptibility of feline herpesvirus-1 to vidarabine, idoxuridine, trifluridine, acyclovir, or bromovinyldeoxyuridine. American Journal of Veterinary Research 50, 158-160.
35. Nasisse M.P., Dorman D.C., Jamison K.C., Weigler B.J., Hawkins E.C., Stevens J.B. (1997). Effects of valacyclovir in cats infected with feline herpesvirus 1. American Journal of Veterinary Research 58, 1141-1144.
36. Owens J.G., Nasisse M.P., Tadepalli S.M., Dormans D.C. (1996). Pharmacokinetics of acyclovir in the cat. Journal of Veterinary Pharmacology and Therapy 19, 488-490.
37. Pedersen N.C., North T.W., Rigg R., Reading C., Higgins J., Leutenegger C., Henderson GL. (2003). 16α-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: initial enhancement leading to long-term suppression. Veterinary Immunology and Immunopathology 94, 133-148.
38. Philpott M.S., Ebner J.P., Hoover E.A. (1992). Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction. Veterinary Immunology and Immunopathology 35, 155-166.
39. Rollinson E.A. (1992). Prospects for antiviral chemotherapy in veterinary-medicine: 1. feline virus diseases. Antiviral Chemistry and Chemotherapy 3, 249-262.
40. Sandmeyer L.S., Keller C.B., Bienzle D. (2005a). Effects of cidofovir on cell death and replication of feline herpesvirus-1 in cultured feline corneal epithelial cells. American Journal of Veterinary Research 66, 217-222.
41. Sandmeyer L.S., Keller C.B., Bienzle D. (2005b). Effects of interferon-α on cytopathic changes and titers for feline herpesvirus-1 in primary cultures of feline corneal epithelial cells. American Journal of Veterinary Research 66, 210-216.
42. Sheets M.A., Unger B.A., Giggleman G.F., Tizard I.R. (1991). Studies of the effect of Acemannan on retrovirus infections: clinical stabilization of feline leukemia virus-infected cats. Molecular Biotherapy 3, 41-45.
43. Smyth N.R., Bennett M., Gaskell R.M., McCracken C.M., Hart C.A., Howe J.L. (1994). Effect of 3′azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Research in Veterinary Science 57, 220-224.
44. Stiles J. (2000). Feline Herpesvirus. Veterinary Clinics of North America: Small Animal Practice 30, 1001-1014.
45. Stiles J., Townsend W.M., Rogers Q.R., Krohne S.G. (2002). Effect of oral administration of L-lysine on conjunctivitis caused by feline herpesvirus in cats. American Journal of Veterinary Research 63, 99-103.
46. Tizard I. (1991). Use of immunomodulators as an aid to clinical management of feline leukemia virus-infected cats. Journal of the American Veterinary Medical Association 199, 1482-1485.
47. Truyen U., Blewaska S., Schultheiss U. (2002). Untersuchung der antiviralen Wirksamkeit von Interferon-Omega (IFN-ω) gegen ausgewälhte Viren von Hund und Katze. Der Praktische Tierarzt 83, 862-865.
48. Uckun F.M., Chen C., Samuel P., Pendergrass S., Venkatachalam T.K., Waurzyniak B., Qazi S. (2003). In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrobial Agents and Chemotherapy 47, 1233-1240.
49. Vahlenkamp T.W., De Ronde A., Balzarini J., Naesens L., De Clercq E., van Eijk M.J.T., Horzinek M.C., Egberink H.F. (1995). (R)-9-(2- Phosphonylmethoxypropyl)-2,6-Diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 39, 746-749.
50. Van Pelt D.R., Lappin M.R. (1994). Pathogenesis and treatment of feline rhinitis. Veterinary Clinics of North America: Small Animal Practice 24, 807-823.
51. Weiss R.C. (1989). Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. American Journal of Veterinary Research 50, 1672-1677.
52. Weiss R.C., Cummins J.M., Richards A.B. (1991). Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. Journal of the American Veterinary Medical Association 199, 1477-1481.
53. Williams D.L., Fitzmaurice T., Lay L., Forster K., Hefford J., Budge C., Blackmore K., Robinson J.C., Field H.F. (2004). Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study. Current Eye Research 29, 215-218.
54. Zapor M.J., Cozza K.L., Wynn GH., Wortmann G.W., Armstrong S.C. (2004). Antiretrovirals, Part II: Focus on Non-Protease Inhibitor Antiretrovirals (NRTIs, NNRTIs, and Fusion Inhibitors). Psychosomatics 45, 524-535.
55. Zeidner, N.S., Myles M.H., Mathiason-DuBard C.K., Dreitz M.J., Mullins J.I., Hoover E.A. (1990). Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrobial Agents Chemotherapy 34, 1749-1756.
56. Zhang W., Mauldin J.K., Schmiedt C.W., Brockus C.W., Boudinot F.D., McCrackin Stevenson M.A. (2004). Pharmacokinetics of zidovudine in cats. American Journal of Veterinary Research 65, 835-840.